Asset Details
Do you wish to reserve the book?
The effect of tolvaptan on renal progression and systemic inflammation in ADPKD
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The effect of tolvaptan on renal progression and systemic inflammation in ADPKD
Do you wish to request the book?
The effect of tolvaptan on renal progression and systemic inflammation in ADPKD
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The effect of tolvaptan on renal progression and systemic inflammation in ADPKD
2025
Overview
Inflammation plays a crucial role in the progression of autosomal dominant polycystic kidney disease (ADPKD). While tolvaptan is primarily known for its vasopressin V2 receptor antagonism, its potential anti-inflammatory effects remain under investigation. This study aimed to evaluate the impact of tolvaptan on inflammatory markers and renal progression in ADPKD patients. This retrospective, two-center cohort study included 80 ADPKD patients, with 40 receiving tolvaptan and 40 serving as controls. Inflammatory markers, including C-reactive protein (CRP), systemic inflammatory index (SII), platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), and renal function parameters such as glomerular filtration rate (GFR) and proteinuria, were analyzed over a 1-year follow-up period. In the tolvaptan group, CRP, SII, PLR, proteinuria, and uric acid levels significantly decreased, whereas these markers increased in the control group. GFR remained stable in the tolvaptan group but declined significantly in the control group (
p
< 0.001). No significant correlation was found between GFR and inflammatory markers in either group. Our findings suggest that tolvaptan may contribute to reducing systemic inflammation in ADPKD patients while preserving renal function. These results align with previous studies indicating a link between inflammation and ADPKD progression.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 692/4022
/ 692/53
/ 692/699
/ ADPKD
/ Adult
/ Antidiuretic Hormone Receptor Antagonists - therapeutic use
/ C-Reactive Protein - metabolism
/ Cysts
/ Female
/ Glomerular Filtration Rate - drug effects
/ Humanities and Social Sciences
/ Humans
/ Kinases
/ Male
/ Males
/ Polycystic Kidney, Autosomal Dominant - drug therapy
/ Polycystic Kidney, Autosomal Dominant - pathology
/ Polycystic Kidney, Autosomal Dominant - physiopathology
/ Science
